Cancer Screening for Seniors: What to Continue, What to Stop, and What Medicare Covers

Adults 65 and older account for approximately 60% of all new cancer diagnoses in the United States each year. Cancer risk accumulates over a lifetime — which means seniors face their peak cancer risk precisely at the age when screening decisions become more complex.

The question at this stage is not whether to worry about cancer, but which screenings still make sense. Turning 65 doesn’t mean cancer screening is over. For most healthy 65-year-olds, it should continue. But age alone is no longer the only variable: life expectancy, functional status, comorbidities, and personal goals now shape the calculus. A healthy 68-year-old and a frail 68-year-old with advanced heart failure have very different screening situations — even though they’re the same age.

The good news at 65: Medicare Part B begins covering most USPSTF-recommended preventive cancer screenings at $0 cost-sharing. The year you turn 65 is an excellent time to take stock of your screening status and make a plan with your primary care provider.

The Life Expectancy Framework: How to Think About Screening After 65

Cancer screening delivers its benefit over time. A colonoscopy at 65 that prevents colorectal cancer produces its mortality benefit over the following 10–15 years. A mammogram at 72 that detects an early breast tumor benefits a woman who lives to see her 80s. The math breaks down when life expectancy is too short to realize the gain — or when treatment that would follow a diagnosis is too burdensome for the patient to tolerate.

This is why guideline bodies have shifted to life expectancy–based language for older adults, rather than strict upper age cutoffs. The cutoffs that do exist (prostate PSA not recommended at 70+, for example) reflect populations where the benefit-to-harm ratio has shifted sufficiently for most, not all, seniors.

According to the Social Security Administration’s 2023 actuarial tables, a 65-year-old American man can expect to live approximately 18 additional years; a 65-year-old woman, approximately 21 years. Most healthy 65-year-olds have substantial remaining life expectancy — the calculus becomes more nuanced only as health declines.

Three Questions Every Senior Should Ask About Screening

1. “What is my estimated life expectancy given my current health?” Most screening benefits require 5–10 years of remaining life. Validated tools like ePrognosis (eprognosis.ucsf.edu) can help estimate this.
2. “If screening finds something, would I be a candidate for treatment?” Frail patients or those with serious comorbidities may not tolerate surgery, chemotherapy, or radiation. If treatment is not an option you’d choose or tolerate, the value of detection is limited.
3. “What are my personal goals?” If your goals prioritize comfort over aggressive treatment, screening may not align. If your goals include longevity and you’d want treatment, screening continues to make sense.

Cancer Screenings to Continue After 65

For healthy seniors with no significant comorbidities, the following screenings should continue.

Breast Cancer Mammography (Women)

Ages 65–74: USPSTF Grade B continues — biennial mammography, covered by ACA and Medicare Part B. The benefit is well-established in this age group.

Ages 75 and above: USPSTF has insufficient evidence (Grade I). However, Medicare Part B covers annual mammography at $0 with no upper age limit. ACS recommends continuing as long as life expectancy is 10 or more years. For healthy women in their late 70s, this typically means continuing. The lead time from mammography detection to mortality benefit is approximately 7–10 years — this needs to fit within your likely remaining life expectancy.

Colorectal Cancer Screening (Ages 65–75)

USPSTF Grade A through age 75 — one of the strongest evidence-based screening recommendations. At 65, if you haven’t been screened recently, begin immediately.

For seniors who find colonoscopy preparation difficult or who have conditions increasing procedural risk, annual FIT (fecal immunochemical test) is an excellent alternative. FIT requires no bowel prep, no sedation, and is performed at home — USPSTF rates it as equivalent to colonoscopy for average-risk adults when done consistently every year.

Lung Cancer LDCT (Ages 65–80, Eligible Smokers)

Eligible smokers between ages 65 and 80 (20+ pack-years, currently smoking or quit within 15 years) should continue annual LDCT. The upper age limit is 80 — USPSTF has no evidence-based recommendation beyond that. Medicare Part B covers annual LDCT for eligible beneficiaries.

Cervical Cancer Screening (Women — Ending at 65)

Cervical cancer screening stops at age 65 for women with adequate prior history: three or more consecutive negative Pap smears, or two or more negative co-tests or primary HPV tests, all within the past 10 years, with the most recent within 5 years. Women who meet this standard should stop — there is no benefit from continuing.

Exception: Women with a history of high-grade cervical dysplasia (CIN 2 or CIN 3) or cervical cancer should continue for at least 25 years after their most recent treatment, even if this extends past age 65.

Cancer Screenings That Slow Down or Stop After 65

Prostate Cancer PSA (Men 70+)

USPSTF 2018 Grade D: recommends against PSA-based prostate cancer screening for men 70 and older. The reasoning is data-driven: most prostate cancer in elderly men is slow-growing. Autopsy studies show that up to 75% of men who die of other causes in their 70s would be found to have prostate cancer at autopsy. PSA screening detects this non-lethal cancer, leads to biopsy anxiety and potentially to treatment whose side effects (incontinence, erectile dysfunction) are more severe and less recoverable in older men. ACS similarly advises no prostate screening if life expectancy is less than 10 years.

Colorectal Cancer (Ages 76 and Above)

Ages 76–85 (USPSTF Grade C): Individualized decision. For someone with adequate prior screening history and average health, the benefit of additional colonoscopy decreases. For someone never screened, a one-time colonoscopy may still be appropriate. Colonoscopy complication risk increases significantly at 75+.

Ages 86+ (USPSTF Grade D): Recommends against colorectal cancer screening. The evidence of benefit at this age is insufficient, and procedural risks are meaningful.

What Medicare Part B Covers: Your Free Preventive Screenings

When you enroll in Medicare Part B at 65, most major preventive cancer screenings become available at $0 cost-sharing (using Medicare-participating providers).

PSA note: Medicare covers PSA annually for men 50+. However, USPSTF recommends against PSA at 70+. Medicare coverage and guideline recommendation are separate — coverage does not mean endorsement.

How Comorbidities and Frailty Affect Screening Decisions

Conditions That May Lead to Stopping Screening

Moderate-to-severe dementia: Patients with dementia may not participate safely in procedures, understand a diagnosis, or meaningfully choose between treatments. If treatment would not be pursued regardless, finding the cancer provides no benefit. Dementia care planning should include explicit cancer screening goals discussions with family or healthcare proxies.

End-stage organ failure: Advanced heart failure (NYHA Class IV), severe oxygen-dependent COPD, or end-stage renal disease often limit life expectancy enough that most cancer screening benefits are not achievable.

Active malignancy with limited prognosis: Patients receiving palliative care for metastatic cancer do not need screening for a second primary cancer.

Conditions That Don’t Automatically Stop Screening

Well-controlled hypertension, well-managed type 2 diabetes, osteoarthritis, mild-to-moderate depression, and stable coronary artery disease without severe heart failure do not by themselves limit life expectancy sufficiently to alter screening for a typical 65–74-year-old. “I take blood pressure medication” is not a reason to stop cancer screening.

Frailty and Procedural Risk

The Fried Frailty Phenotype identifies frailty when three or more of the following are present: unintentional weight loss (>10 lbs in past year), self-reported exhaustion, weak grip strength, slow walking speed, and low physical activity. Frail older adults face higher colonoscopy complication rates, recover more slowly from surgery, and may not tolerate standard chemotherapy. For frail seniors, annual FIT is generally preferable to colonoscopy for CRC screening; mammography is lower-risk than invasive alternatives.

Anticoagulants and Colonoscopy

Many seniors take anticoagulants (warfarin, rivaroxaban, apixaban, dabigatran) or antiplatelet therapy. These do not preclude colonoscopy but require coordination with your prescribing physician — timing and bridging require planning. Mention your blood thinners explicitly when scheduling a colonoscopy.

Talking to Your Doctor: Key Questions for Senior Screening Decisions

1. “Based on my current health and conditions, which cancer screenings do you recommend I continue?”
2. “What is my estimated life expectancy? Are there validated tools you can use to estimate this?”
3. “If we found cancer through screening, would I realistically be a candidate for treatment?”
4. “What are the procedural risks — colonoscopy, biopsy — at my age and with my health conditions?”
5. “Are there less invasive alternatives to colonoscopy that would work for me?”

Bringing your medication list and a summary of health conditions allows your provider to give you a precise, individualized recommendation rather than a generic one.

Cancer Screening Summary by Age Band

Frequently Asked Questions